Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-129,950
Closed -$28M 159
2024
Q1
$28M Buy
129,950
+13,250
+11% +$3.1M 0.6% 37
2023
Q4
$30.2M Buy
116,700
+43,800
+60% +$10.8M 1.11% 24
2023
Q3
$18.7M Buy
72,900
+53,300
+272% +$14.3M 0.48% 42
2023
Q2
$5.58M Buy
+19,600
New +$5.83M 0.13% 73

Other funds holding BIIB

Zimmer Partners's BIIB Position: Q2 2024 in Review

Zimmer Partners sold out of Biogen (BIIB) in Q2 2024, closing a stake of 129,950 shares — an estimated $28M sold.

Zimmer Partners first reported a position in BIIB in Q2 2023 and held it in 4 quarters. The position peaked at $30.2M in Q4 2023. 943 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

  • Zimmer Partners reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
  • Zimmer Partners sold 129,950 Biogen shares in Q2 2024, an estimated $28M.
  • Zimmer Partners first reported a position in Biogen in Q2 2023 and held it in 4 quarters.
  • Zimmer Partners's Biogen position peaked at $30.2M in Q4 2023.
  • 943 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Zimmer Partners's 13F filing for Q2 2024, filed 14 Aug 2024.